Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
17 08 2023
17 08 2023
Historique:
medline:
21
8
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.
Identifiants
pubmed: 37595560
pii: S0092-8674(23)00809-7
doi: 10.1016/j.cell.2023.07.031
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3523-3523.e1Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.